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Background: Hypergammaglobulinemia is frequently observed in patients with chronic liver disease (CLD) of
different causes. On the other hand, elevated levels of serum immunoglobulin G (IgG) are the best diagnostic
marker for autoimmune hepatitis (AIH). Thus, the ability to distinguish AIH patients from patients with
other liver disease, especially patients with advanced liver cirrhosis, is important since most AIH patients will
a have favorable treatment response if diagnosed properly.
Objective: We conducted this study to evaluate the significance of elevated IgG levels in patients with non-
autoimmune CLD and to compare these IgG levels with those in patients with AIH upon diagnosis.
Setting and study population: The serum IgG levels in 27 patients with AIH determined at the time of
diagnosis were compared to the serum IgG levels in 27 patients with other CLDs of variable severity at the
King Abdul Aziz University Hospital in Jeddah, Saudi Arabia. Severity of the disease was evaluated in all
patients.
Results: We found that the patients in the CLD group with decompensated cirrhosis had significantly higher
serum IgG levels compared to the compensated CLD patients (pB0.02). In addition, the AIH patients had
significantly higher serum IgG levels than the non-autoimmune hepatitis CLD patients and the
decompensated cirrhosis patients in the CLD group (pB0.001 and pB0.044, respectively). Most patients
with elevated serum IgG of the AIH group (67%) and the CLD group (75%) had significant
hypergammaglobulinemia, not just isolated elevated IgG levels.
Conclusion: Elevated serum IgG levels with hypergammaglobulinemia are commonly found in patients with
advanced CLD. The differentiation of such cases from AIH is important in order to avoid misdiagnosis and
confusion with AIH.
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C
hronic liver diseases (CLD), especially decom-
pensated cirrhosis, are recognized by abnormal
immunological responses, including autoantibo-
dies and hypergammaglobulinemia (1). Hypergammaglo-
bulinemia is thought to be a marker for histologically
advanced forms of fibrosis (2) and may play a role in the
progression of liver disease (3). It has been suggested that
hypergammaglobulinemia in CLD patients is due to the
diminished removal of immunoglobulins by the diseased
liver (4). On the other hand, elevated levels of immuno-
globulins G and M (IgG and IgM) are important
diagnostic markers for autoimmune hepatitis (AIH) and
primary biliary cirrhosis (PBC), respectively (5, 6). The
diagnosis of AIH is based on the criteria that were
established and modified by the international AIH group,
which include predominant elevation in the levels of
serum aminotransferases, negative markers for viral
hepatitis, the exclusion of genetic liver diseases, the
absence of toxic or alcohol liver injury, the presence of
autoantibodies for AIH, elevated levels of serum IgG,
and histological features of AIH (7). A serum IgG level of
1.5-fold greater than the normal level, and more recently
1.1-fold greater than the normal level, have been accepted
as diagnostic criteria for AIH (6, 8). Although serum IgG
is not the only diagnostic marker for AIH, a level of 1.44-
fold greater than normal was found to be the best
diagnostic predictor of AIH (8). High serum IgG levels
in patients with advanced cirrhosis (where liver biopsy
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coagulopathy), absence of viral markers and negative
screening for genetic disorders represent diagnostic
difficulties that may lead to confusion with AIH,
especially in patients with autoantibodies-negative AIH
(about 20% of patients with AIH) (9). Correct diagnosis
of AIH is important because even patients with advanced
AIH, if properly diagnosed, will have a favorable treat-
ment response (10). The aim of this study was to evaluate
the significance of elevated serum IgG levels in patients
with non-AIH CLD and to compare these levels to the
IgG levels found in patients with AIH at the time of
diagnosis.
Subjects and methods
A cohort comparative study was performed to compare
theIgGlevels in patientswithAIHat thetimeofdiagnosis
and the IgG levels in patients with other liver disease.
Study population
Patients followed at the hepatology clinic in King Abdul
Aziz University Hospital and who were either diagnosed
with AIH based on the international scoring system (the
AIH group) or were diagnosed with CLD due to other
causes (the CLD group) were included in this study.
Procedure
The data were collected from May to December 2008.
We reviewed the charts of 34 patients with AIH who were
diagnosed between 1995 and 2008 (AIH group). The
patientswere eligible for this study if the diagnosis of AIH
was definite, if the levels of serum IgG at the time of
diagnosis were available in the records and if the records
were complete regarding clinical, immunological, and
biochemical data. Patientswith incomplete data and those
who did not have their serum IgG levels recorded at the
time of diagnosis were excluded. We obtained the data
regardingtheclinicalpresentationsatthetimeofdiagnosis
(whether compensated or decompensated) and liver bio-
chemical parameters, which included serum levels of
alanine aminotransferase (ALT), aspartate amino trans-
ferase, alkaline phosphatase, gamma-glutamyl transfer-
ase, total protein, albumin, and the total and direct
bilirubin. We also obtained the complete blood count
(CBC) and the prothrombin time. We also reviewed the
serum autoimmune profiles, which included antinuclear
antibody (ANA) that were weakly positive (1/40) and
strongly positive (1/1,280), smooth muscle antibody
(SMA), liver kidney microsomal-1 antibodies (LKM-1),
and antimitochondrial antibodies (AMA). Moreover, we
looked at the immunological viral markers, the IgG levels
that were determined at the time of diagnosis by nephe-
lometry, and the results of the liver biopsies, if available.
Twenty-seven patients with other liver diseases (com-
pensated or decompensated) who agreed to provide blood
samples for testing serum IgG levels were also included
(CLD group). We assessed these patients clinically, per-
formed liver biochemical tests, and measured serum IgG
levels like we did for the AIH patient group. The cause of
liver disease in the CLD group was defined by reviewing
the biochemical, serological and immunological data, and
the liver biopsy results. For all patients in the AIH and
CLDgroups,weusedtheclinicalandbiochemicalmarkers
(ascites, hepatic encephalopathy, serum albumin, total
bilirubin, and prothrombin time) to calculate the Child
Pugh score. All of the patients were checked for the
presence of autoimmune diseases other than AIH.
Statistical analysis
We used the statistical package for the social sciences
(SPSS 15) to determine the mean, standard deviation,
and frequencies. We used the independent t-test to
compare the parametric variables, where a p-value
B0.05 was considered statistically significant. In addi-
tion, we used the Receiver Operating Characteristic
(ROC) curve to compare the serum IgG levels between
patients in the AIH and CLD groups.
Results
Between 1995 and 2008, 34 patients had been diagnosed at
the hospital with AIH type 1 based on the AIH diagnostic
criteria and the response to therapy (the AIH group). Of
these, 27 patients were included in this study after
exclusion of seven patients because data on serum IgG
levels at the time of diagnosis were missing. Twenty-seven
patients with other liver diseases were randomly selected
from the hepatology department’s in- and out-patient
sections. The mean age of patients in the AIH group
was 33 years (range 1265 years) while the mean age for
the CLD group with other liver disease was 45.2 years
(range 1675 years). Most of the patients were females in
both the AIH group (22; 81%) and the CLD group (16;
59.3%). Notably, 48% of the patients in the AIH group
and 52% of patients in the CLD group had decompen-
sated cirrhosis. In addition, 26 patients (96.2%) of the
AIH group and 16 patients (59.2%) of the CLD group had
elevated levels of serum IgG.
The mean value of serum IgG in the AIH group was
30.6 g/L913.248 standard deviation (range 14.366 g/L),
whichis1.9-foldgreaterthantheupperlimitofthenormal
range. The mean IgG level of the patients in the CLD
group was 19.2 g/L97.838 standard deviation (range
6.2839.366 g/L), which is 1.19-fold greater than the upper
limit of the normal range. The difference between the two
groups was statistically significant (pB0.001). Similarly,
decompensated cirrhosis patients in the AIH group had
significantly higher levels of serum IgG than the decom-
pensated cirrhosis patients of the CLD group (p0.044).
Ten of the 14 (78.3%) patients in the CLD group with
decompensated cirrhosis had elevated levelsof serum IgG,
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sated CLD patients had elevated levels of serum IgG. In
the CLD group, the decompensated cirrhosis patients had
asignificantlyhigher(pB0.02)levelofIgG(25.3g/L)than
the compensated CLD patients (16.92 g/L). By contrast,
in the AIH group the serum IgG levels in those with
compensated cirrhosis (32.59 g/L916.1494) was higher
(p0.036) than in those with decompensated cirrhosis
(28.59 g/L99.149).
In addition, 67% of the patients in the AIH group had
hypergammaglobulinemia rather than isolated high IgG
levels while 12 of 16 patients (75%) with elevated levels of
IgG in the CLD group had hypergammaglobulinemia.
Furthermore, eight patients in the AIH group had
acute hepatitis at presentation that was reflected by
serum ALT levels and an AST concentration of more
than 5001,000 IU/L, but all of the patients in the CLD
group had CLD.
The autoimmune profiles of the AIH group showed
strongly positive ANA in eight patients (29.6%) and
moderately positive ANA in 11 patients (40.74%), while
the rest of the AIH patients were weakly positive for
ANA. SMA was strongly positive in seven patients
(25.9%), moderately positive in 17 patients (62.9%), and
negative in the rest of the AIH patients. Furthermore, one
patient in the AIH group was positive for LKM-1 and
all of them were negative for AMA. For the CLD group,
17 patients were tested for ANA and 10 of them (58.8%)
were weakly positive (1:401:160), two were moderately
positive (one of them had Grave’s disease), and the rest
were negative. Nine patients from the CLD group were
tested for SMA and only one of them demonstrated a
weakly positive result.
Liver biopsy results were obtained for 15 patients from
the AIH group, and all of them were consistent with a
diagnosis of AIH. The remaining patients of the AIH
group did not have a liver biopsy performed either
because of an advanced stage of the disease that was
coupled with severe coagulopathy or because they refused
the liver biopsy procedure.
Five patients of the AIH group had systemic lupus
erythematosus (SLE), one patient of the CLD group had
Grave’s disease, and one had PBC. The most common
cause of liver disease in the CLD group was chronic
hepatitis C (Table 1).
Discussion
We show that patients with CLD other than AIH also
tend to have elevated serum IgG levels with or without
hypergammaglobulinemia, and that patients with decom-
pensated cirrhosis (51.8% in our study) are more likely to
have elevated serum IgG levels as compared to patients
with compensated CLD. This may indicate that elevated
serum IgG levels are related to the severity of liver disease
rather than to its cause. These findings are similar to the
data reported for patients with chronic hepatitis C (11,
12). Similarly, the most common cause for CLD in our
study was chronic hepatitis C. Immune activation with
positive autoantibodies of variable levels, including ANA,
SMA, LKM-1, and AMA, is another feature of non-AIH
CLD (13, 14). The combination of both hypergammaglo-
bulinemia and positive autoantibodies may confuse the
diagnosis of non-AIH CLD with that of AIH, especially
in patients with advanced liver cirrhosis.
Most of the patients with elevated levels of IgG, in
both groups but particularly in the CLD group (75%),
had hypergammaglobulinemia rather than elevated levels
of serum IgG. Watt and colleagues related similar
findings to the extent of fibrosis and a possible role of
immunoglobulins in the progression of liver disease (3).
Overall, patients with AIH had serum mean IgG levels
that were significantly higher than in patients with other
liver diseases. Using the mean serum IgG level for the
AIH group (30.6 g/L), we obtained a sensitivity of 90
98% and a specificity of about 96% for the diagnosis of
AIH patients (Fig. 1). In our cohort, 81.4% of the
patients with AIH had serum IgG levels above the
mean level of the CLD group, but on the other hand,
three patients (11%) of the CLD group had serum IgG
levels equal to or higher than the mean of the AIH group.
The importance of such findings in CLD patients with
negative viral markers, mildly to moderately elevated
levels of autoantibodies (13, 14) and advanced disease
where liver biopsy may not be helpful, is to avoid the
potential confusion in diagnosing these patients with
AIH. These aforementioned three patients were adminis-
tered trial doses of Prednisolone, but none of them
responded to treatment. On the other hand, 10 patients
from the AIH group with advanced cirrhosis had
favorable responses to the treatment with Prednisolone
and Azathioprine.
One patient in the CLD group had chronic hepatitis C
and he was treated with a combination of Pegylated
interferon and Ribavirin and had a rapid virologic
Table 1. The causes of liver disease in CLD group
Frequency Percentage (%)
Hemochromatosis 2 7.4
Chronic hepatitis C 12 44.4
Chronic hepatitis B 5 18.5
Primary intrahepatic familial
cholestasis
1 3.7
Non-alcoholic steatohepatitis 2 7.4
Congenital liver fibrosis 1 3.7
Primary biliary cirrhosis 1 3.7
Bilharzial liver disease 3 11.1
Total 27 100.0
Significance of high IgG in patients with chronic liver disease
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normal (15.2 g/L). Maruyama and colleagues showed
that the serum IgG levels in chronic Hepatitis C patients
who responded to treatment were reduced compared to
non-responders (2). On the other hand, the response to
treatment in patients with AIH will be predicted by the
reduction of the serum ALT, AST, and IgG levels (10).
The limitation of our study is the small sample size.
Similar studies with a larger number of patients may help
in defining the cut-off level of IgG that can help in
differentiating patients with AIH from patients with other
advanced liver diseases. This would be of value because
using the most recently published diagnostic criteria, an
AIH IgG level of 1.1-fold greater than the normal value is
given two points out of six for the diagnosis of AIH (8).
Conclusion
Hypergammaglobulinemia with significantly elevated
levels of IgG is a common finding in patients with
advanced liver cirrhosis of different etiologies. This may
result in the misdiagnosis of AIH in some patients.
Studies on larger number of patients may help to define
a cut-off level of IgG in order to differentiate between
advanced cirrhosis due to AIH and other causes of liver
disease associated with high IgG.
Conflict of interest and funding
The authors have not received any funding or benefits
from industry to conduct this study.
References
1. Wegener M, Neuhausen P, Bo ¨rsch G, Ricken D. Signiﬁcance of
serum immunoglobulins for the diagnosis of alcohol-induced
liver diseases. Dtsch Med Wochenschr. 1986; 111: 171620.
2. Maruyama S, Hirayama C, Horie Y, Yorozu K, Maeda K, Inoue
M, et al. Serum immunoglobulins in patients with chronic
hepatitis C: a surrogate marker of disease severity and treatment
outcome. Hepatogastroenterology 2007; 54: 4938.
3. Watt K, Uhanova J, Gong Y, Kaita K, Doucette K, Pettigrew N,
et al. Serum immunoglobulins predict the extent of hepatic
ﬁbrosis in patients with chronic hepatitis C virus infection. J
Viral Hepat. 2004; 11: 2516.
4. Tanaka S, Okamoto Y, Yamazaki M, Mitani N, Nakqjima Y,
Fukui H. Signiﬁcance of hyperglobulinemia in severe chronic
liver diseases  with special reference to the correlation between
serum globulin/IgG level and ICG clearance. Hepatogastroen-
terology 2007; 54: 23015.
5. Czaja AJ. Diagnosis and therapy of autoimmune liver disease.
Med Clin North Am. 1996; 80: 97394.
6. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK,
Cancado EL, et al. International Autoimmune Hepatitis Group
Report: review of criteria for diagnosis of autoimmune hepatitis.
J Hepatol. 1999; 31: 92938.
7. Bogdanos D, Invernizzi P, Mackay I, Vergani D. Autoimmune
liver serology current diagnostic and clinical challenge. World J
Gastroenterol. 2008; 14: 337487.
8. Hennes EM, Zeniya M, Czaja AJ, Pare ´s A, Dalekos GN,
Krawitt EL, et al. Simpliﬁed criteria for the diagnosis of
autoimmune hepatitis. Hepatology 2008; 48: 16976.
9. Johnson PJ, McFarlane IG. Meeting report: International
Autoimmune Hepatitis Group. Hepatology 1993; 18: 9981005.
10. Czaja1 A, Freese D. Diagnosis and treatment of autoimmune
hepatitis. Hepatology 2002; 36: 47997.
11. Gonza `lez-Quintela A, Alende MR, Gamallo R, Gonza `lez-Gil P,
Lo ´pez-Ben S, Tome ´ S, et al. Serum immunoglobulins (IgG,
IgA, IgM) in chronic hepatitis C. A comparison with non-
cirrhotic alcoholic liver disease. Hepatogastroenterology 2003;
50: 21216.
12. El-Kady IM. Assessment of humoral immune response in
patients with chronic hepatitis C virus infection. Egypt J
Immunol. 2004; 11: 1417.
13. Bayraktar Y, Bayraktar M, Gurakar A, Hassanein TI, Van
Thiel DH. A comparison of the prevalence of autoantibodies in
individuals with chronic hepatitis C and those with autoimmune
hepatitis: the role of interferon in the development of auto-
immune diseases. Hepatogastroenterology 1997; 44: 41725.
14. Ghonaim M, Al-Ghamdi A, El-Bana H, Bakr A, Ghoneim E,
El-Edel R, et al. Autoantibodies in chronic liver disease. Egypt J
Immunol. 2005; 12: 10111.
*Hind I. Fallatah
Department of Medicine
King Abdul Aziz University Hospital
PO Box 9714, Jeddah 21423
Saudi Arabia
Tel: +966 501267336
Fax: +966 26751149
Email: hindfallatah@hotmail.com
Fig. 1. ROC curve for serum IgG level in autoimmune
hepatitis compared to other chronic liver disease. Area under
the curve equals 0.902.
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